Premium
Violacein antimicrobial activity on Staphylococcus epidermidis and synergistic effect on commercially available antibiotics
Author(s) -
Dodou H.V.,
Morais Batista A.H.,
Sales G.W.P.,
Medeiros S.C.,
Rodrigues M.L.,
Nogueira P.C.N.,
Silveira E.R.,
Nogueira N.A.P.
Publication year - 2017
Publication title -
journal of applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.889
H-Index - 156
eISSN - 1365-2672
pISSN - 1364-5072
DOI - 10.1111/jam.13547
Subject(s) - staphylococcus epidermidis , antimicrobial , microbiology and biotechnology , antibiotics , staphylococcus aureus , biofilm , biology , chemistry , bacteria , genetics
Aims The study aimed to assess whether violacein has antimicrobial activity on Staphylococcus epidermidis and synergistically modulates the action of commercially available antimicrobial drugs. Methods and Results Violacein showed excellent antimicrobial activity on biofilm‐forming and nonbiofilm‐forming S. epidermidis strains ( ATCC 35984) ( ATCC 12228), with bacteriostatic ( MIC = 20 μ g ml −1 and 10 μ g ml −1 respectively) and bactericidal effects ( MBC = 20 μ g ml −1 for both strains), observed in short periods of exposure. The violacein bactericidal concentration led to S. epidermidis death after 2–3 h of exposure. Additionally, violacein synergistically modulated the activity of different antimicrobial classes on S. epidermidis ATCC 12228 (81·8%; n = 9) and on S. epidermidis ATCC 35984 (54·5%; n = 6), reducing the MIC of these antibiotics by up to 16‐fold. Conclusion Violacein shows excellent antimicrobial activity on S. epidermidis strains. Significance and Impact of the Study Violacein shows the potential for the development of a new drug for the treatment of infections caused by S. epidermidis .